The study was conducted in patients with moderately to severely active rheumatoid arthritis who previously completed the VOLTAIRE-RA study.
Results from a phase 3b extension study of Boehringer Ingelheim’s (BI) biosimilar adalimumab, Cyltezo, showed similar safety, efficacy, and immunogenicity to reference adalimumab, Humira.
The study was conducted in patients with moderately to severely active rheumatoid arthritis (RA) who previously completed VOLTAIRE-RA, which was a 58-week, randomized, double-blind, parallel-arm equivalence trial of Cyltezo and US-sourced Humira in 15 sites in 14 countries.
In the open-label extension study (VOLTAIRE-RAext), eligible patients had completed 48 weeks’ treatment with Cyltezo (Group A), 24 weeks each of reference adalimumab and then Cyltezo (Group B), or 48 weeks of reference adalimumab (Group C) in VOLTAIRE-RA.
In total, 430 patients received Cyltezo every 2 weeks for 48 weeks:
Over 2 years, Cyltezo showed similar safety, efficacy, and immunogenicity to Humira, independent of initial treatment in the original trial.
The proportion of patients with drug-related adverse events (AEs)—20.2% overall—was similar across all 3 groups: A (21.3%), B (20.4%), and C (17.6).
Researchers did not identify any new AEs. Most treatment-emergent AEs were minor and of mild to moderate intensity, and most drug-related AEs were similar to Humira’s, such as infections and infestations.
Clinical responses seen at the end of VOLTAIRE-RA were sustained during the extension study, and all efficacy and immunogenicity end points were similar across groups.
Previous research has already demonstrated the structural similarity and comparable functionality of BI’s Cyltezo, which was approved by the FDA in 1997, and Humira. In addition, the VOLTAIRE-PK study established 3-way pharmacokinetic similarity between Cyltezo and both EU- and US-approved Humira, and another study demonstrated that switching from the reference drug to the biosimilar had no impact on efficacy, safety, or immunogenicity.
Reference
Cohen SB, Czeloth N, Lee E, Klimiuk PA, Peter N, Jayadeva G. Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext) [published online August 6, 2019]. Expert Opin Biol Ther. doi: 10.1080/14712598.2019.1645114.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5
March 9th 2024The adalimumab biosimilar SB5 was reported to be as safe and effective as the reference product in a review of randomized controlled trials and real-world studies on immune-mediated inflammatory diseases.